Lantheus Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Lantheus Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $343.37M | Feb 20, 2019 |
| FY2018 | Dec 31, 2017 | $331.38M | Feb 20, 2019 |
| FY2018 | Dec 31, 2016 | $301.85M | Feb 20, 2019 |
| FY2017 | Dec 31, 2015 | $293.46M | Feb 26, 2018 |
| FY2016 | Dec 31, 2014 | $301.60M | Feb 23, 2017 |
| FY2015 | Dec 31, 2013 | $283.67M | Mar 2, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.54B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.53B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.30B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $935.06M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $425.21M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $339.41M | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | $89.35M | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | $85.78M | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | $85.71M | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | $86.51M | Feb 25, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $81.24M | Feb 26, 2018 |
| FY2017 | Sep 30, 2017 | $79.94M | Feb 26, 2018 |
| FY2017 | Jun 30, 2017 | $88.84M | Feb 26, 2018 |
| FY2017 | Mar 31, 2017 | $81.36M | Feb 26, 2018 |
| FY2017 | Dec 31, 2016 | $74.35M | Feb 26, 2018 |
| FY2017 | Sep 30, 2016 | $73.06M | Feb 26, 2018 |
| FY2017 | Jun 30, 2016 | $77.97M | Feb 26, 2018 |
| FY2017 | Mar 31, 2016 | $76.47M | Feb 26, 2018 |
| FY2016 | Dec 31, 2015 | $71.20M | Feb 23, 2017 |
| FY2016 | Sep 30, 2015 | $74.12M | Feb 23, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $941.95M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $988.29M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $709.54M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $581.70M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $187.70M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $138.76M | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | $44.57M | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | $41.59M | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | $44.57M | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | $44.08M | Feb 25, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $233.56M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $312.44M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $326.66M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $28.07M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($71.28M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | ($13.47M) | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | $10.45M | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | $4.86M | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | $6.41M | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | $9.95M | Feb 25, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $310.83M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $456.98M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $364.64M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $36.20M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($60.83M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | ($4.20M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $51.66M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $64.49M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $51.85M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $56.59M | Feb 20, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $177.31M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $168.10M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $77.71M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $311.68M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $44.97M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $32.79M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $20.02M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $17.07M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $18.13M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $12.20M | Feb 20, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $390.14M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $544.75M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $305.26M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $281.78M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $53.92M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $16.40M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $80.38M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $61.19M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $54.78M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $49.64M | Feb 20, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.23B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.98B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.65B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $1.32B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $863.78M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $869.82M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $405.92M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $439.83M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $383.86M | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $255.90M | Feb 26, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.14B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $892.33M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $835.26M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $874.11M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $399.35M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $355.62M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $291.32M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $368.83M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $360.57M | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $362.41M | Feb 26, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.09B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.09B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $815.89M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $447.15M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $464.44M | Feb 26, 2025 |
| FY2023 | Dec 31, 2020 | $514.21M | Feb 22, 2024 |
| FY2022 | Dec 31, 2019 | $114.60M | Feb 23, 2023 |
| FY2021 | Dec 31, 2018 | $71.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $23.29M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | ($106.52M) | Feb 25, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $239.52M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $61.19M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $61.19M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $61.19M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $61.19M | Feb 23, 2023 |
| FY2022 | Dec 31, 2020 | $58.63M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $15.71M | Feb 24, 2022 |
| FY2019 | Dec 31, 2018 | $15.71M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $15.71M | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $15.71M | Feb 26, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $679.50M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $445.95M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $133.50M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($193.16M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($221.23M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($149.95M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($136.47M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($168.14M) | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | ($209.01M) | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | ($332.40M) | Feb 26, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $359.12M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $912.81M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $713.66M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $415.65M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $98.51M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $79.61M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $92.92M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $113.40M | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | $76.29M | Feb 20, 2019 |
| FY2018 | Dec 31, 2016 | $51.18M | Feb 20, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $558.07M | Feb 23, 2023 |
| FY2021 | Dec 31, 2021 | $174.76M | Feb 24, 2022 |
| FY2020 | Dec 31, 2020 | $218.40M | Feb 25, 2021 |
| FY2019 | Dec 31, 2019 | $194.07M | Feb 25, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 4 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 25, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 4 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 25, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 64.59M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 68.45M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 69.86M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 68.85M | Feb 22, 2024 |
| FY2021 | Dec 31, 2021 | 67.74M | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | 66.88M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 39.25M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 39.25M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | 38.47M | Feb 20, 2019 |
| FY2019 | Dec 31, 2016 | 38.47M | Feb 25, 2020 |